XPO1 and plasma cell myeloma: Due to the tremendous impact of the inhibitor of Xpo1 in multiple myeloma [6], we may expect that targeting the nuclear-cytoplasmic machinery may be translated into Ph+ leukemias to provide new therapeutic chances.